Eli Lilly’s stock rises

Eli Lilly stock higher following surprise weight loss treatment data
Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.
Eli Lilly Stock Hits 3-Week High, Boosts Retail Mood On Zepbound’s Edge Over Wegovy In Weight-Loss Trial Showdown
Eli Lilly shares rose nearly 1.6% on Wednesday morning to three-week highs after the company unveiled promising results from a clinical trial that pitted its popular weight-loss drug against Novo Nordisk’s Wegovy.
Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data. Click for my update on LLY and NVO.
Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal
Eli Lilly & Co. Inc.’s stock rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.
Eli Lilly Touts Upbeat Weight-Loss Drug Results
Eli Lilly (LLY) stock is rising after the company said its weight-loss drug achieved better results than Wegovy
Why Is Eli Lilly and Company (LLY) Among Ken Fisher’s Top Stock Picks Heading Into 2025?
We recently compiled a list of the Billionaire Ken Fisher’s Top 15 Stock Picks Heading Into 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against Ken Fisher’s other top stock picks.
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
Eli Lilly’s stock rises after its Zepbound weight-loss drug achieved better results than rival Wegovy in a head-to-head trial
Eli Lilly & Co. Inc.’s stock rose 2% early Wednesday, after the company said a study comparing its Zepbound weight-loss drug to rival Novo Nordisk’s Wegovy showed an average weight loss of 20.2% of body weight compared with 13.
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
Eli Lilly & Co. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?
Eli Lilly stock popped on news President Joe Biden proposed Medicare and Medicaid pay for weight-loss drugs. Is LLY stock a ...
Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?
Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion ...
Eli Lilly & Co (LLY) Gets a Buy from Jefferies
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
Stock Market Today: Dow futures rise close to record ahead of Powell comments
The well-received results from Salesforce.com are having an outsized impact on the Dow -- the software maker's current ...
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...
Eli Lilly’s Growth Driven by Strong Prescription Trends for Mounjaro and Zepbound
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...